tiprankstipranks
Trending News
More News >

Praxis Precision assumed with an Outperform at Oppenheimer

Oppenheimer analyst Jay Olson assumed coverage of Praxis Precision (PRAX) with an Outperform rating and $97 price target following quarterly results. Given the multiple upcoming readouts across its pipeline, the firm remains encouraged by management’s execution. For the vomatrigine program, Oppenheimer looks forward to the RADIANT and POWER1 registrational Phase 2/3 topline results, still expected in mid-2025 and the second half of 2025, respectively.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1